Can amylin analogue lead to better diabetes control?
Morrow
Thomas
T
Matria Health Care, USA.
D000682:Amyloid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001786:Blood Glucose / Q000032:analysis; D002986:Clinical Trials as Topic; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy* / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000517:prevention & control; D019468:Disease Management; D005934:Glucagon / Q000097:blood / Q000502:physiology; D006801:Humans; D007004:Hypoglycemic Agents / Q000145:classification / Q000627:therapeutic use; D007328:Insulin / Q000009:adverse effects / Q000627:therapeutic use; D008329:Managed Care Programs; D014481:United States; D015430:Weight Gain / Q000187:drug effects
D000682:Amyloid; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D005934:Glucagon